Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals announced an amendment to its collaboration with Torii Pharmaceutical to jointly conduct a global pivotal Phase 3 clinical trial for YCANTH® in treating common warts, expected to start in the first half of 2025. The cost will be equally shared, with Torii funding Verrica's portion through future payment offsets. Verrica highlighted the significant commercial prospects for YCANTH, given the 22 million common wart patients in the U.S. alone and no FDA-approved treatments. Torii will also make an $8 million milestone payment to Verrica upon the first patient dosing in Japan. The trial's initiation depends on feedback from the FDA and Japan's PMDA.
Verrica Pharmaceuticals Inc. reported $3.2M revenue for YCANTH® in Q1 2024. Over 228M lives covered by commercial insurance. Phase 2 results for VP-315 expected in Q2 2024. Conference call scheduled. Key achievements include FDA status, J-Code, and distribution agreements. Financially, $3.2M in product revenue, $0.6M in collaboration revenue. Increased expenses in SG&A and R&D. Net loss of $20.3M.
Verrica Pharmaceuticals Inc. announced that its President and CEO will present at upcoming investor conferences hosted by RBC Capital Markets and HCW BioConnect. The webcasts can be accessed on the company's website for 90 days after the events.
Verrica Pharmaceuticals Inc. will provide a corporate update and report its first-quarter 2024 financial results on May 13, 2024. The company, focused on dermatology therapeutics, will host a conference call and live webcast to discuss its financial performance and future prospects. Investors can participate via telephone or webcast to learn about Verrica's progress and financial status.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.